Evaluation of Osteonecrosis Risk Using Serum C-Terminal Cross-Linked Telopeptide of Type 1 Collagen (CTX-1) Levels in Osteoporotic Patients: Effects of Drug Holidays and Risk Factors
Open Access
- 12 January 2026
- journal article
- Published by AVES YAYINCILIK A.Ş. in The Eurasian Journal of Medicine
- Vol. 58 (1) , 1-6
Abstract
Background: The aim of this study is to evaluate the risk of osteonecrosis of the jaw in patients receiving osteoporosis treatment using C-terminal cross-linked telopeptide of type 1 collagen (CTX-1) values, to analyze follow-ups after drug holidays, and to compare treatment agents and other risk factors to determine the association with CTX-1 results. Methods: A total of 273 patients (266 female and 7 male) who received bisphosphonate and denosumab treatment for osteoporosis were included in this retrospective study. Sociodemographic characteristics, vitamin D levels, serum CTX-1 level, presence of diseases affecting CTX-1 levels, type of bisphosphonate, duration of use, presence of drug holidays, and duration of denosumab use (if any) were recorded. The effects of bisphosphonates and denosumab on CTX-1 levels were compared, and differences in the risk of osteonecrosis between them were evaluated. Results: In this study, a meaningful association was not identified between serum CTX-1 levels and the measured vitamin D values (P = .232). Patients who underwent a drug holiday had significantly higher mean serum CTX-1 levels (266.2 Å} 175.1 pg/mL) compared to those without a drug holiday (199.9 Å} 138.5 pg/ mL; P = .009). Higher CTX-1 levels were observed in individuals receiving ibandronate and alendronate, whereas the lowest values were detected in patients treated with denosumab. Conclusion: Serum CTX-1 levels appeared unaffected by vitamin D. Although the denosumab group exhibited the highest risk of osteonecrosis, the difference compared to zoledronic acid was not statistically significant. These results suggest caution during jaw-related procedures and consideration of drug holidays when necessary. Cite this article as: Ergül EE, Laçin O, Kılıçaslan HÖ, et al. Evaluation of osteonecrosis risk using serum C-terminal cross-linked telopeptide of type 1 collagen (CTX-1) levels in osteoporotic patients: Effects of drug holidays and risk factors. Eurasian J Med. 2026, 58(1), 1104, doi:10.5152/eurasianjmed.2026.251104.Keywords
This publication has 31 references indexed in Scilit:
- Associations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German childrenScientific Reports, 2015
- Pathophysiology of Osteonecrosis of the JawsOral and Maxillofacial Surgery Clinics of North America, 2015
- Biomarkers for Bisphosphonate‐Related Osteonecrosis of the JawClinical Implant Dentistry and Related Research, 2015
- Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: A 1-year double-blind RCT in postmenopausal womenJournal of Bone and Mineral Research, 2013
- Dental complications and management of patients on bisphosphonate therapy: A review articleJournal of Oral Biology and Craniofacial Research, 2013
- Serologic Bone Markers for Predicting Development of Osteonecrosis of the Jaw in Patients Receiving BisphosphonatesJournal of Oral and Maxillofacial Surgery, 2010
- Clinical Investigation of C-Terminal Cross-Linking Telopeptide Test in Prevention and Management of Bisphosphonate-Associated Osteonecrosis of the JawsJournal of Oral and Maxillofacial Surgery, 2009
- Effect of vitamin D supplementation on bone and vitamin D status among Pakistani immigrants in Denmark: a randomised double-blinded placebo-controlled intervention studyBritish Journal of Nutrition, 2008
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJournal of Oral and Maxillofacial Surgery, 2003
- Ethnic Variation in Bone Turnover in Pre- and Early Perimenopausal Women: Effects of Anthropometric and Lifestyle FactorsThe Journal of Clinical Endocrinology & Metabolism, 2002